Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(3):303-325. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0022

View: 3573 Download: 269 Web of Science: 1 Crossref: 2

Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu

Clin Mol Hepatol. 2024;30(2):279-280. Published online March 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0191

View: 2116 Download: 54 Web of Science: 1 Crossref: 1

Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho

Received August 29, 2024 Accepted October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0734 [Accepted]

View: 245 Download: 60

1 |

Viewed By 5157	MAFLD: How is it different from NAFLD?
Viewed By 4901	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4875	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4589	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4570	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search